<DOC>
	<DOCNO>NCT01433497</DOCNO>
	<brief_summary>The purpose study compare safety efficacy masitinib 6 mg/kg/day versus placebo treatment patient primary progressive multiple sclerosis relapse-free secondary progressive multiple sclerosis .</brief_summary>
	<brief_title>A Phase 2b/3 Study Compare Efficacy Safety Masitinib Placebo Treatment Patients With Primary Progressive Relapse-free Secondary Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>1 . Patient suffer either primary progressive secondary progressive multiple sclerosis without relapse within 2 year inclusion accord revise McDonald 's criterion 2 . Patient EDSS score [ 2.0 6.0 ] inclusive baseline 3 . Patient EDSS score progression â‰¥ 1 point confirm second evaluation carry least 6 month apart , within 2 year inclusion 1 . Patient suffer disease MS would well explain patient 's neurological clinical sign symptom and/or MRI lesion 2 . Patient MRI examination injection gadolinium contrast agent use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>primary progressive</keyword>
	<keyword>relapse-free</keyword>
	<keyword>secondary progressive</keyword>
</DOC>